Molecular Studies and Clinical Correlations in Human Prostatic Disease

Prostate Cancer Clinical Trial

Official title:

Molecular Studies and Clinical Correlations in Human Prostatic Disease

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00578240
• Other study ID #: 90-040
• Status: Active, not recruiting
• Start date: April 1990
• Est. completion date: December 2025

Study information

• Verified date: August 2023
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The Genitourinary Oncology/Urology Services at Memorial Sloan-Kettering Cancer Center (MSKCC) participates in research for the control, treatment, and cure of cancer. The purpose of this study is to collect normal and cancerous tissues, in addition to blood, and other body fluid samples from men with prostate cancer or prostatic disease. These samples may be stored for future use or used immediately by researchers who study prostate cancer and try to find better ways to diagnose, prevent, and treat it. We will look for genetic changes and protein markers on these cells. We hope to learn more about what makes some people get prostate cancer, why some cancers are more aggressive than others, and why some cancers respond to or resist different treatments. We may also try to grow the tumor cells in the lab. We may find a new treatment for prostate cancer based on this research.

Description:

The therapeutics program for advanced prostate cancer is based on the hypothesis that the factors contributing to and associated with progression change as the disease evolves. To categorize these changes we now consider the disease as a series of states. 1 The states represent points where an intervention might be considered to prevent cancer from developing, to eliminate established disease, or to delay progression. The states also represent clinically significant milestones that can be used to assess treatment effects.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 5290
• Est. completion date: December 2025
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: Male
• Age group: N/A and older

Eligibility

Inclusion Criteria:

Men with prostate conditions representing the following disease states:

• No Cancer Diagnosis
• Clinically Localized Disease
• Rising PSA
• Clinical Metastases: Noncastrate
• Clinical Metastases: Castrate (Testosterone = 50 ng/ml)
• Signed informed consent Exclusion Criteria: -Patients without any prostate related problems.

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Diseases

Locations

Country	Name	City	State
United States	Memorial Sloan Kettering Cancer Center	New York	New York

Sponsors (55)

Lead Sponsor

Collaborator

Memorial Sloan Kettering Cancer Center

Advanced Cell Diagnostics, ApoCell, Inc., Array Genomics, Beckman Coulter GmbH, Biocept, Inc., Bioview, Inc., Broad Institute, Brooklyn ImmunoTherapeutics, LLC, Clearbridge BioMedics Pte Ltd., Singapore, Cold Spring Harbor Laboratory, Creatv Microtech, Inc., Cynvenio Biosystems, Dana-Farber Cancer Institute, Duke University, Epic Sciences, Exosome Diagnostics, Inc., Flinders Medical Centre, Fluxion Biosciences, Foundation Medicine, Fred Hutchinson Cancer Center, Gen-Probe, Incorporated, Genentech, Inc., General Electric, Ikonysis, Innocrin Pharmaceuticals Inc., Institute of Cancer Research, United Kingdom, Janssen Diagnostics, LLC, Johns Hopkins University, M.D. Anderson Cancer Center, Massachusetts Institute of Technology, Nodality, Ohio State University, Oregon Health and Science University, Palo Alto Research Center, Promega Corporation, Purdue University, Rarecells, Rockefeller University, Rutgers Cancer Institute of New Jersey, Serametrix Corporation, Silicon Biosystems, The Scripps Research Institute, Universitätsklinikum Hamburg-Eppendorf, University of California, San Francisco, University of Chicago, University of Michigan, University of Minnesota, University of Regensburg, University of Southern California, University of Washington, University of Wisconsin, Madison, Viatar LLC, Vitatex Inc., Weill Medical College of Cornell University

Country where clinical trial is conducted

United States, 

External Links

•   Memorial Sloan Kettering Cancer Center